GeoVax

GeoVax is a clinical-stage biotechnology company initially established primarily to develop an effective and safe vaccine against HIV-1, but has since expanded its platform to target other infectious diseases and cancer. The company's goal is to create vaccines for many serious human diseases for which there are significant unmet medical needs. GeoVax' novel development platform builds on the proven clinical and commercial success of the Modified Vaccinia Ankara vector technology, with improvements to antigen design and state-of-the-arm manufacturing capabilities. GeoVax technology approach uses recombinant DNA or recombinant viruses to produce virus-like particles in the person being vaccinated. In human clinical trials of the company's HIV vaccines, GeoVax demonstrated that VLPs are safe and eliciting both strong and durable humoral and cellular immune response.